or Try an Advanced Search...

    Technical Analysis for LXRX - Lexicon Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 1.63 0.31% 0.01
    LXRX closed down 4.42 percent on Wednesday, April 17, 2024, on 1.15 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Apr 30
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical LXRX trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.31%
    Expansion Breakdown Bearish Swing Setup 0.31%
    Lower Bollinger Band Walk Weakness 0.31%
    Wide Bands Range Expansion 0.31%
    Below Lower BB Weakness 0.31%
    Down 3 Days in a Row Weakness 0.31%
    Down 4 Days in a Row Weakness 0.31%
    Lower Bollinger Band Touch Weakness 0.31%
    Oversold Stochastic Weakness 0.31%
    Fell Below 200 DMA Bearish -4.13%
    Older End-of-Day Signals for LXRX ...

       Recent Intraday Alerts

    Alert Time
    Gap Up Closed 13 minutes ago
    200 DMA Resistance about 2 hours ago
    Possible Inside Day about 2 hours ago
    60 Minute Opening Range Breakout about 2 hours ago
    Rose Above 200 DMA about 2 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    LXRX Chart by TradingView
    Basic chart:

    Profile

    Lexicon Pharmaceuticals, Inc. Description

    Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Life Sciences Clinical Development Diabetes Monoclonal Antibodies Drug Discovery Clinical Trial Rheumatoid Arthritis Ulcerative Colitis Human Diseases Ulcer Colitis Glaucoma Irritable Bowel Syndrome Treatment Of Glaucoma Biotie Therapies

    Is LXRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 Lexicon Pharmaceuticals to Host 2024 Investor Day
    Apr 16 All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
    Apr 3 Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    Mar 25 Lexicon Pharmaceuticals files to sell 57.66M shares for holders
    Mar 25 Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
    Mar 13 Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
    Mar 12 Lexicon stock slides 8% after rallying 30% in prior session
    Mar 12 New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
    Mar 12 Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
    Mar 11 Lexicon Pharmaceuticals GAAP EPS of -$0.20 in-line, revenue of $0.7M misses by $1.24M
    See more LXRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.789
    52 Week Low 0.9201
    Average Volume 4,853,158
    200-Day Moving Average 1.71
    50-Day Moving Average 2.37
    20-Day Moving Average 2.09
    10-Day Moving Average 1.95
    Average True Range 0.18
    RSI (14) 31.51
    ADX 15.68
    +DI 16.68
    -DI 30.92
    Chandelier Exit (Long, 3 ATRs) 2.05
    Chandelier Exit (Short, 3 ATRs) 2.15
    Upper Bollinger Bands 2.52
    Lower Bollinger Band 1.67
    Percent B (%b) -0.05
    BandWidth 40.84
    MACD Line -0.15
    MACD Signal Line -0.10
    MACD Histogram -0.0494
    Fundamentals Value
    Market Cap 395.32 Million
    Num Shares 244 Million
    EPS -0.77
    Price-to-Earnings (P/E) Ratio -2.10
    Price-to-Sales 1100.41
    Price-to-Book 4.17
    PEG Ratio -0.14
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.88
    Resistance 3 (R3) 1.90 1.84 1.83
    Resistance 2 (R2) 1.84 1.78 1.83 1.82
    Resistance 1 (R1) 1.73 1.73 1.70 1.71 1.80
    Pivot Point 1.67 1.67 1.66 1.66 1.67
    Support 1 (S1) 1.56 1.61 1.53 1.54 1.44
    Support 2 (S2) 1.50 1.56 1.49 1.42
    Support 3 (S3) 1.39 1.50 1.41
    Support 4 (S4) 1.37